Vyome Holdings (HIND) Common Equity (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Common Equity of $8.0 million for Q1 2026, up 271.64% year-over-year from $2.2 million in Q1 2025, and up 113.75% quarter-over-quarter from $3.8 million in Q4 2025.
Vyome Holdings (HIND) Common Equity (2015 - 2026) Analysis & Trends
Vyome Holdings' Common Equity history runs 12 years deep, the most recent figure standing at $8.0 million for Q1 2026.
- In Q1 2026, Common Equity rose 271.64% year-over-year to $8.0 million; the TTM figure through Mar 2026 stood at $8.0 million (up 271.64% YoY), while the FY2025 annual figure was $3.8 million, up 185.67% from the prior year.
- Common Equity for Q1 2026 stood at $8.0 million, up from $3.8 million in the prior quarter.
- The five-year high for Common Equity was $37.0 million in Q1 2022, with the low at -$6.3 million in Q1 2024.
- The 5-year median for Common Equity is $3.7 million (2022), against an average of $5.2 million.
- The sharpest annual moves came in 2023 and 2026: Common Equity sank 268.65% in 2023, then surged 271.64% in 2026.
- Vyome Holdings' Common Equity stood at $3.7 million in 2022, then tumbled by 268.65% to -$6.2 million in 2023, then climbed by 28.88% to -$4.4 million in 2024, then jumped by 185.67% to $3.8 million in 2025, then jumped by 113.75% to $8.0 million in 2026.
- Business Quant data shows HIND's Common Equity at $8.0 million in Q1 2026, $3.8 million in Q4 2025, and $3.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Vyome Holdings | 16.00 Mn | 8.11 Mn | 11,658.00 | 7.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.31 Mn |
| Mar 31, 2026 | 8.04 Mn |
| Dec 31, 2025 | 3.76 Mn |
| Sep 30, 2025 | 3.92 Mn |
| Jun 30, 2025 | -4.99 Mn |
| Mar 31, 2025 | -4.69 Mn |
| Dec 31, 2024 | -4.39 Mn |
| Sep 30, 2024 | -4.09 Mn |
| Jun 30, 2024 | -3.97 Mn |
| Mar 31, 2024 | -6.30 Mn |
| Dec 31, 2023 | -6.17 Mn |
| Sep 30, 2023 | 3.08 Mn |
| Jun 30, 2023 | 6.74 Mn |
| Mar 31, 2023 | 7.76 Mn |
| Dec 31, 2022 | 3.66 Mn |
| Sep 30, 2022 | 18.95 Mn |
| Jun 30, 2022 | 30.78 Mn |
| Mar 31, 2022 | 36.96 Mn |
| Dec 31, 2021 | 44.33 Mn |
| Sep 30, 2021 | 79.31 Mn |